RMD — ResMed Inc.

ResMed Inc. Q3 Fiscal Year 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $1.43 billion, an 11% increase year-over-year (8% growth on a constant currency basis).
• Gross Margin: 62.8%, up 290 basis points year-over-year and 50 basis points sequentially.
• Operating Profit: Increased by 18%, with an operating margin of 36.7%.
• Non-GAAP Earnings Per Share (EPS): Increased by 21%, with a net income growth of 20%.
• Free Cash Flow: $520 million, reflecting strong operational performance and disciplined working capital management.
• Shareholder Returns: $262 million returned through dividends and share repurchases, with a quarterly dividend of $0.60 per share.

2. Strategic Updates and Business Highlights

• Leadership Change: Brett Sandercock announced his retirement, with Aaron Blumer appointed as the new CFO.
• Product Innovation: Continued rollout of fabric-based masks (AirTouch N30i, F30i Comfort, F30i Clear) showing strong market adoption and improved patient compliance.
• Acquisition: Agreement to acquire Noctrix Health for $340 million, expected to close on June 1, 2026. Noctrix's product, NIDRA, treats restless leg syndrome and is anticipated to enhance ResMed's sleep health portfolio.
• Digital Health Ecosystem: Ongoing investments in digital health capabilities to streamline patient engagement and adherence to therapy.

3. Forward Guidance and Outlook

• Revenue Growth: Expectation of high single-digit revenue growth and earnings growth exceeding revenue growth through fiscal year 2030.
• Gross Margin: Anticipated to remain in the range of 62% to 63% for fiscal year 2026.
• Operating Expenses: SG&A expenses projected to be 19% to 20% of revenue, while R&D expenses expected to be 6% to 7% of revenue.

4. Challenges and Points of Concern

• Component Cost Pressures: Potential cost inflation on components due to geopolitical uncertainties and fuel costs, although ResMed aims to mitigate this through supply chain efficiencies.
• Market Dynamics: Concerns regarding funding models (e.g., Synapse) and their impact on DME customers, although management believes these changes are manageable.
• Competitive Pressures: While ResMed maintains a strong market position, there is an acknowledgment of increasing competition in the devices segment, particularly from new entrants.

5. Notable Q&A Insights

• Component Costs: Management addressed concerns about rising component costs, emphasizing their strategies to maintain gross margin improvements despite external pressures.
• Noctrix Acquisition: The acquisition is expected to enhance growth and profitability, with management confident in leveraging ResMed's existing market access to accelerate Noctrix's growth.
• U.S. Device Market: Management noted stable growth in U.S. devices despite some seasonality and reaffirmed confidence in their ability to capture market share through innovative products.
• Primary Care Engagement: The effectiveness of CME programs in converting primary care physicians into prescribers was discussed, highlighting a focus on increasing referral volumes rather than solely targeting new prescribers.

Overall, ResMed Inc. reported a strong quarter with solid growth metrics, strategic acquisitions, and a focus on innovation, while also navigating some external challenges and competitive pressures.